Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS) (PAPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03228823|
Recruitment Status : Recruiting
First Posted : July 25, 2017
Last Update Posted : June 12, 2019
Premature ventricular contractions (PVCs) coexist in patients with heart failure (HF) and LV dysfunction. Frequent PVCs have shown to induce a reversible cardiomyopathy (PVC-CM).
This clinical pilot study will enroll 36 patients with frequent PVCs (burden >10%) and CM (LVEF <45%) and randomize them to either: 1) RFA or 2) AADs. Prior to treatment, patients will undergo a baseline cardiac MR if clinically indicated followed by 3-month observation period (optimal HF medical therapy). Changes in LV function/scar, PVC burden/arrhythmias and clinical/functional status (QOL, HF symptoms and admissions, NYHA class) and adverse events will be assessed throughout the observation period and compare with PVC suppression strategies (RFA or AAD). Similar comparison will be made between RFA and AAD treatment groups during a 12-month follow up using a Prospective Randomized Open, Blinded End-point (PROBE) study design. The treatment regimens will be compared in an intention-to-treat analysis. In addition, a total of 20,000 consecutive ambulatory ECG Holter monitors from all participating centers will be screened to identify all patients with probable diagnosis of PVC-CM.
This pilot study is intended to estimate the prevalence of this clinical entity and pave the way for a large full scale randomized trial to identify best treatment strategy for patients with PVC-CM. Treating and reversing this underestimated PVC-CM may improve patient's health and subsequently decrease HF healthcare spending.
|Condition or disease||Intervention/treatment||Phase|
|Ventricular Premature Beats, Contractions, or Systoles Cardiomyopathies||Procedure: Radiofrequency ablation Drug: Amiodarone (Antiarrhythmic drug)||Phase 4|
Rationale. Frequent PVCs have shown to induce a reversible cardiomyopathy (PVC-CM). Yet, it is unclear why some patients develop PVC-CM, while others do not. Appropriate diagnosis and treatment of patients with PVC-CM is believed to carry significant benefits, improving quality of life (QOL), HF symptoms / admissions and life expectancy. Currently, these patients are offered radiofrequency ablation (RFA), antiarrhythmic drugs (AADs) or no treatment depending on physician's experience and resources. Nevertheless, no randomized-prospective study exists to support the benefit of RFA. Thus, a large-scale multicenter randomized clinical trial entitled "Prospective Assessment of PVC Suppression in Cardiomyopathy (PAPS)"' study has been planned to compare these treatment strategies. However, a PAPS pilot study is proposed to better estimate the potential affected patient population, limitations of enrollment, rate of clinical outcomes, potential crossover and drop out. This pilot study is key to better design and power the large-scale multicenter PAPS trial.
Objective. PAPS pilot study is a randomized clinical trial to assess the feasibility of enrolling, randomizing treatment strategies and retaining participants with frequent PVCs and associated CM.
Hypotheses. Our main hypotheses of the PAPS pilot study are:
- A large-scale randomized PAPS clinical study is feasible with minimal barriers of enrollment, treatment crossover and drop out due to a unique design including a short observation period and PVC suppression strategy in all participants.
- The rate of responders (defined as improvement of LVEF ≥ 10% points) with HF medical therapy alone during observation period will be less than 15%. In contrast, RFA and AADs will have a responder rate of at least 35% in the same population. Furthermore, RFA will have a greater 1-year response rate when compared to AAD therapy.
- RFA will have a lower rate of composite adverse events (worsening NYHA class, HF admission, treatment side effects & complications, and death), arrhythmia burden and a better long-term tolerance than AADs.
Methods. A prospective clinical pilot study is planned to prove the feasibility of a large-scale multicenter clinical trial (PAPS study) of patients with probable PVC-CM. This pilot study will enroll 36 patients with frequent PVCs (burden ≥10%) and CM (LVEF ≤45%) and randomize them to either: 1) RFA or 2) AADs. Prior to treatment, all patients will undergo a baseline cardiac MR if clinically indicated and be allowed a 3-month observation period (optimal HF medical therapy). To assess the effects of PVC suppression, changes in LV function, rate of responders (defined above), PVC burden/arrhythmias and clinical/functional status (QOL, HF symptoms and admissions, NYHA class) and adverse events will be compared between observation period and both PVC suppression strategies (RFA or AAD). To identify the best PVC suppression strategy, similar comparisons between RFA and AAD treatment groups will be performed at 12-month follow up using a Prospective Randomized Open, Blinded End-point (PROBE) study design. The treatment regimens will be compared in an intention-to-treat analysis.
In summary, the multicenter PAPS pilot study is intended to better estimate the prevalence of PVC-CM, prove feasibility and rates of clinical outcomes. This pilot study with a multidisciplinary approach will pave the way for a large-scale randomized PAPS trial to identify the best treatment strategy for patients with PVC-CM. Treating and reversing PVC-CM with its associated HF morbidity and mortality will impact not only healthcare spending, but most importantly it will improve patient's health, quality of life and long-term prognosis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||PVC suppression with either antiarrhythmic drugs or radiofrequency ablation|
|Masking:||None (Open Label)|
|Official Title:||Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS): A Pilot Study|
|Actual Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||August 31, 2021|
|Estimated Study Completion Date :||August 31, 2021|
Active Comparator: Radiofrequency Ablation
Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
Procedure: Radiofrequency ablation
RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
Other Name: Ablation
Active Comparator: Antiarrhythmic Drug
Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
Drug: Amiodarone (Antiarrhythmic drug)
AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
Other Name: Amiodarone
- Improvement of left ventricular ejection fraction after PVC suppression [ Time Frame: 12 months ]Compare the overall improvement or change in LVEF between RFA and AAD groups.
- Responders to PVC suppression strategy [ Time Frame: 12 months ]Assessment of the number of responders (delta LVEF ≥ 10%) after PVC suppression strategies will assess the effectiveness of RFA and AADs to reverse or improve cardiomyopathy induced by frequent PVCs.
- Successful PVC suppression [ Time Frame: 12 months ]Efficacy of Radiofrequency ablation vs. Antiarrhythmic drugs to achieve successful PVC suppression (defined as a reduction of PVC burden greater than ≥80%).
- Composite Adverse Events [ Time Frame: 12 months ]Composite end-point of adverse events, including worsening in NYHA functional class (I-IV), number of HF and cardiac-related admissions, RFA complications and AAD adverse effects and cardiovascular death.
- Composite Arrhythmia Burden [ Time Frame: 12 months ]Composite end-point of arrhythmia burden, including PVC recurrence, non-sustained (< 30sec) and sustained (> 30sec) ventricular arrhythmias and arrhythmic sudden cardiac death
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03228823
|Contact: Jose F Huizar, M.D.||firstname.lastname@example.org|
|Contact: Pamela K Summers, BS, CCRPemail@example.com|
|United States, California|
|University of California Los Angeles Medical Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Julie Sorg, R.N., M.S.N.|
|Contact: Marmar Vaseghi, M.D., Ph.D. 310 206 2235 firstname.lastname@example.org|
|Principal Investigator: Marmar Vaseghi, M.D., Ph.D.|
|University of California, San Francisco||Recruiting|
|San Francisco, California, United States, 94143|
|Contact: Sara Yogi, B.A. 415-502-3803 email@example.com|
|Contact: Edward Gerstenfeld, M.D. 415-476-5706 firstname.lastname@example.org|
|Principal Investigator: Edward Gerstenfeld, M.D.|
|Principal Investigator: Teresa DeMarco, M.D.|
|United States, Florida|
|James A. Haley Veterans' Hospital||Not yet recruiting|
|Tampa, Florida, United States, 33612|
|Contact: Visola Alimova 813-972-2000 ext 5293 email@example.com|
|Principal Investigator: Raymond Cutro, MD|
|Sub-Investigator: Fabio Leonelli, MD|
|Sub-Investigator: David Wilson, MD|
|United States, Illinois|
|Rush University Medical Center||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Kelli Jones, R.N. 312-942-8707 firstname.lastname@example.org|
|Contact: Parikshit Sharma, M.D. 312-942-8707 email@example.com|
|Principal Investigator: Parikshit Sharma, M.D.|
|United States, Massachusetts|
|Roxbury VA Medical Center||Not yet recruiting|
|West Roxbury, Massachusetts, United States, 02132|
|Contact: Adelqui Peralta, M.D. 857-203-6841 firstname.lastname@example.org|
|Principal Investigator: Adelqui Peralta, M.D.|
|United States, New York|
|Northwell Health System-Staten Island University Hospital||Recruiting|
|Staten Island, New York, United States, 10305|
|Contact: Richard Dima 718-226-1489 email@example.com|
|Contact: Marcin Kowalski, M.D. 718-226-4645 firstname.lastname@example.org|
|Principal Investigator: Marcin Kowalski, M.D.|
|United States, Pennsylvania|
|University of Pennsylvania Medical Center||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Mary Gnap, R.N. 215-349-8446 email@example.com|
|Contact: David Frankel, M.D. 215-662-6801 firstname.lastname@example.org|
|Principal Investigator: David Frankel, M.D.|
|United States, Virginia|
|McGuire VA Medical Center||Recruiting|
|Richmond, Virginia, United States, 23249|
|Contact: Pamela K Summers, B.S., CCRP 804-675-5000 ext 6831 email@example.com|
|Contact: Donna Sargent, R.N., BSN 804-675-5466 firstname.lastname@example.org|
|Principal Investigator: Jose F Huizar, M.D.|
|Sub-Investigator: Karoly Kaszala, M.D., Ph.D.|
|Sub-Investigator: Alex Y Tan, M.D.|
|Virginia Commonwealth University||Recruiting|
|Richmond, Virginia, United States, 23298|
|Contact: Kenneth A Ellenbogen, M.D. 804-628-0147 kenneth.Ellenbogen@vcuhealth.org|
|Contact: Melissa Hockman, R.N., B.S.N. (804) 675-5167 email@example.com|
|Principal Investigator: Kenneth A Ellenbogen, M.D.|
|Principal Investigator: Adam Sima, Ph.D.|
|Libin Cardiovascular Institute, University of Calgary||Not yet recruiting|
|Calgary, Alberta, Canada, T2N 2T9|
|Contact: Jennifer McKeage, R.N. 403-210-6047 firstname.lastname@example.org|
|Contact: Carlos A. Morillo, M.D. 403-944-2670 email@example.com|
|Principal Investigator: Carlos A Morillo, M.D.|
|Study Director:||Jose F Huizar, M.D.||McGuire VA Medical Center|